Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial
ASCO 2026
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus palbociclib vs letrozole plus palbociclib as first-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (Abstract LBA1006).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Giredestrant is being designed as an oral SERD and complete ER antagonist. We've already seen two positive phase III trials with giredestrant, evERA in combination with everolimus in the metastatic setting and lidERA as a single agent better than standard endocrine therapy in the adjuvant setting. So persevERA is the third phase III study to report with giredestrant, and this looked at the first-line setting in patients with metastatic ER-positive, HER2-negative advanced breast cancer. Standard of care here is, of course, an aromatase inhibitor and a CDK4/6 inhibitor. And persevERA was designed to assess whether switching from an AI to giredestrant could improve PFS. So the study randomized just under 1,000 patients between letrozole and palbociclib and giredestrant and palbociclib in a double-blind fashion. And the primary endpoint was investigator-assessed PFS. Overall, the study was negative. There was no statistically significant improvement in PFS. The hazard ratio was 0.89, but there clearly appeared to be a numerical improvement of PFS with giredestrant. The curves, interestingly, appeared to be overlapping for the first 12 months, perhaps suggesting that early recurrences are not driven by ER; they're driven by other mechanisms of resistance, and then the curves appear to separate. Potentially, giredestrant here is active because these later recurrences are driven, it's preventing the emergence of ESR1 mutations. And so, overall, the study does confirm the high activity of giredestrant, but not better than an aromatase inhibitor in this study combined with palbociclib.
The ASCO Post Staff
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included in the Plenary Session.
The ASCO Post Staff
Jana de Boniface, MD, PhD, of Capio Saint Göran's Hospital and Karolinska Institutet, reviews overall survival and patient-reported arm morbidity findings from the SENOMAC trial, which sought to determine if patients with breast cancer and sentinel lymph node macrometastases could omit complete axillary dissection (Abstract LBA503).
The ASCO Post Staff
Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choice for first-line therapy among patients with HLA-A2–negative metastatic uveal melanoma (Abstract LBA9503).
The ASCO Post Staff
Angimar Uriepero-Palma, MD, of Jefferson Einstein Philadelphia Hospital, discusses a study that showed use of sodium-glucose cotransporter 2 (SGLT2) inhibitors was associated with longer 3-year overall survival and a lower risk of cytopenias and infections among diabetic patients with chronic lymphocytic leukemia (CLL) receiving Bruton’s tyrosine kinase inhibitors (Abstract 7051).
Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) classified as unfit or frail per geriatric assessment or not eligible for anthracycline chemotherapy due to reduced ejection function or prior exposure (Abstract 7002).